A cyclic melanocortin-receptor peptide used as a reference in GPCR and receptor-binding research.
What it is
Bremelanotide (PT-141) is a cyclic melanocortin-receptor peptide with formula C50H68N14O10 and an average molecular weight near 1025.2. Its cyclic architecture stabilizes the receptor-binding conformation, and it falls within the melanocortin research category.
Research and regulatory context
PT-141 has been developed and approved as a medicine in some markets. For laboratory purposes it is supplied only as a reference reagent and is widely used as a tool compound in melanocortin-receptor pharmacology research, particularly studies of MC1R and MC4R.
Why it is referenced
As a well-characterized melanocortin agonist, PT-141 is a common positive control in GPCR binding and signaling assays. Reference lots are specified at ≥98% HPLC purity to support reproducible receptor-pharmacology work in vitro.
Every PT-141 order includes a sealed, lot-controlled vial, the completed lot documentation, and a handling & storage card. Product-specific handling follows the supplied documentation and institutional SOPs.
Evidence limits and research safety
Research findings can differ by model, assay, purity, formulation, and study design. Published cell, biochemical, and pre-clinical observations do not establish human or veterinary safety, efficacy, dosing, or suitability. Researchers should review the applicable SDS, institutional safety procedures, waste requirements, and lot-specific documentation before handling any reference material.
Related research
Explore the peptide collection